AAAAAA
Results:
1-7
|
Results: 7
Authors:
QUINLAN DM
MCGLASHAN TH
SCHULDBERG D
GLAZER W
Citation: Dm. Quinlan et al., CORE NEGATIVE AND POSITIVE SYMPTOMS IN SCHIZOPHRENIA, Schizophrenia research, 24(1-2), 1997, pp. 20-20
Authors:
MCGLASHAN TH
QUINLAN D
GLAZER W
SCHULDBERG D
Citation: Th. Mcglashan et al., COGNITIVE-FUNCTIONING AND PERSISTENTLY HIGH NEGATIVE SYMPTOMS IN CHRONIC-SCHIZOPHRENIA, Schizophrenia research, 24(1-2), 1997, pp. 115-115
Authors:
QUINLAN DM
MCGLASHAN TH
SCHULDBERG D
GLAZER W
Citation: Dm. Quinlan et al., NEGATIVE SYMPTOM AND NEUROPSYCHOLOGICAL PRECURSORS OF TARDIVE-DYSKINESIA, Schizophrenia research, 24(1-2), 1997, pp. 272-272
Authors:
WEIDEN P
GLAZER W
Citation: P. Weiden et W. Glazer, ASSESSMENT AND TREATMENT SELECTION FOR REVOLVING-DOOR INPATIENTS WITHSCHIZOPHRENIA, Psychiatric quarterly, 68(4), 1997, pp. 377-392
Authors:
SLATER EJ
GLAZER W
Citation: Ej. Slater et W. Glazer, USE OF OBRA-87 GUIDELINES FOR PRESCRIBING NEUROLEPTICS IN A VA NURSING-HOME, Psychiatric services, 46(2), 1995, pp. 119-121
Authors:
QUINLAN DM
SCHULDBERG D
MORGENSTERN H
GLAZER W
Citation: Dm. Quinlan et al., POSITIVE AND NEGATIVE SYMPTOM COURSE IN CHRONIC COMMUNITY-BASED PATIENTS - A 2-YEAR PROSPECTIVE-STUDY, British Journal of Psychiatry, 166, 1995, pp. 634-641
Authors:
GLAZER W
Citation: W. Glazer, DEPOT NEUROLEPTICS - COST-EFFECTIVE AND UNDERUTILIZED, JAMA, the journal of the American Medical Association, 272(22), 1994, pp. 1722-1722
Risultati:
1-7
|